Marincek, Nicolas

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2017 | 2015 | 2014 | 2013 | 2012

2017

Umlauft, Maria; Radojewski, Piotr; Spanjol, Petar Marko; Dumont, Rebecca; Marincek, Nicolas; Kollár, Attila; Brunner, Philippe; Beyersmann, Jan; Müller-Brand, Jan; Maecke, Helmut R; Laimer, Markus; Walter, Martin Alexander (2017). Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic Issues. Journal of nuclear medicine, 58(9), p. 1532. Society of Nuclear Medicine 10.2967/jnumed.117.190660

2015

Dumont, Rebecca A; Seiler, Daniela; Marincek, Nicolas; Brunner, Philippe; Radojewski, Piotr; Rochlitz, Christoph; Müller-Brand, Jan; Maecke, Helmut R; Briel, Matthias; Walter, Martin Alexander (2015). Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. American journal of nuclear medicine and molecular imaging, 5(1), pp. 46-55.

2014

Ng, Quinn Kwan-Tai; Olariu, Cristina I; Yaffee, Marcus; Taelman, Vincent F; Marincek, Nicolas; Krause, Thomas Michael; Meier, Lorenz; Walter, Martin Alexander (2014). Indium-111 labeled gold nanoparticles for in-vivo molecular targeting. Biomaterials, 35(25), pp. 7050-7057. Elsevier 10.1016/j.biomaterials.2014.04.098

Romer, A.; Seiler, D.; Marincek, Nicolas; Brunner, P.; Koller, M. T.; Ng, Quinn Kwan-Tai; Maecke, H. R.; Müller-Brand, J.; Rochlitz, C.; Briel, M.; Schindler, C.; Walter, Martin Alexander (2014). Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 41(2), pp. 214-222. Springer 10.1007/s00259-013-2559-8

2013

Marincek, Nicolas; Jörg, Ann-Catherine; Brunner, Philippe; Schindler, Christian; Koller, Michael T.; Rochlitz, Christoph; Müller-Brand, Jan; Maecke, Helmut R.; Briel, Matthias; Walter, Martin Alexander (2013). Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. Journal of translational medicine, 11, p. 17. BioMed Central 10.1186/1479-5876-11-17

2012

Villard, Linda; Romer, Anna; Marincek, Nicolas; Brunner, Philippe; Koller, Michael T; Schindler, Christian; Ng, Quinn K T; Mäcke, Helmut R; Müller-Brand, Jan; Rochlitz, Christoph; Briel, Matthias; Walter, Martin A (2012). Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of clinical oncology, 30(10), pp. 1100-6. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.37.2151

Provide Feedback